Panjin Zhongrun High Performance Polymers Co., Ltd. Overview
Panjin Zhongrun High Performance Polymers was one of China's early private attempts to make polyetheretherketone (PEEK) resin domestically at commercial scale. It was founded in 2009 in the Panjin petrochemical cluster of Liaoning Province. It used the nucleophilic polycondensation route developed at Jilin University and held four synthesis patents covering polysulfone-family resins and copolymerised PEEK. The company built a Phase 1 plant with a nameplate capacity of up to 1,000 t/y and marketed its resin under the CoPEEK brand. By 2012 it was pursuing export markets through an exclusive European distribution agreement with Hamburg-based Bieglo. Its claimed capacity matched that of the eventual domestic leader, Zhongyan. Its commercial traction, however, appears to have been limited: industry directories in 2017 described its operating rate as unknown. By December 2022, a competitor's regulatory filing reported its business licence as revoked. The company is best understood today as a cautionary case study in China's PEEK import-substitution drive, not as an operating competitor.
What the company did
Panjin Zhongrun was a resin-synthesis company. It sat in the mid-stream polymerisation step of the PEEK value chain. That step converts aromatic monomers into polymer powder and pellets. The monomers are principally 4,4'-difluorobenzophenone (氟酮, "fluoroketone") and hydroquinone. The reaction uses a carbonate condensing agent in a high-boiling solvent, typically diphenyl sulfone. The company's own published description, as reproduced in a 2017 Aibang directory, emphasised three things:
Four synthesis patents: covering different methods of producing polysulfone (PSU), polyethersulfone (PES), polyether ether sulfone (PEES), biphenyl polyether ether sulfone (PPSU), and copolymerised PEEK (CoPEEK).
-
A Phase 1 project of 1,000 t/y of CoPEEK production capacity.
-
Use of the Jilin University nucleophilic synthesis route.
A separate Chinese industry article (China Advanced Materials Industry Expo, undated) stated that the 1,000 t/y CoPEEK unit had entered production and sales. It also claimed that this capacity ensured consistent CoPEEK quality.
Company's own description from its latest annual report
Not available. As a private limited company, Panjin Zhongrun publishes no annual report. PRC companies must file an annual report summary with the State Administration for Market Regulation (SAMR) via the National Enterprise Credit Information Publicity System. Revocation of a business licence often follows failure to make these filings.
Business model and revenue model
| Dimension | Characterisation | Evidence quality |
|---|---|---|
| Revenue model | Product sales (resin powder and pellets); no service, subscription, or licensing revenue identified | Moderate (inferred from product listings and distributor agreement) |
| Product vs. service mix | ~100% product (estimated qualitatively; no figures disclosed) | Low |
| Licensing | Held 4 synthesis patents; no evidence of out-licensing | Low |
| Go-to-market | Direct domestic sales plus third-party distribution abroad (Bieglo, Europe, from 2012) | Moderate |
| Pricing posture | Positioned on price competitiveness versus Western incumbents, while arguing that value-in-use, not price, decides customer choice | Moderate (Plasteurope interview with sales director Steven Xu, 2012) |
Value-chain position
| Value-chain stage | Typical players | Panjin Zhongrun role |
|---|---|---|
| Monomers (fluoroketone, hydroquinone) | Jiangsu Xinhan, Yingkou Xingfu, Zhongxin Fluorine; Eastman/Mitsui (photo-grade hydroquinone) | Buyer (not disclosed which suppliers) |
| Polymerisation (resin synthesis) | Victrex, Syensqo/Solvay, Evonik, Zhongyan, Jida Tesu, Pengfulong | Core activity |
| Compounding (GF/CF/wear grades) | Resin makers plus compounders | Limited; only unreinforced CoPEEK grades identified |
| Stock shapes (rod, sheet, tube) | Ningbo Zheneng, Jiangsu Junhua, Ensinger etc. | Customer segment |
| Component fabrication / OEM | Electronics, auto, oil & gas, medical | End markets |
Customer types and end-markets (independent characterisation)
The company did not disclose customer lists. By analogy with Zhongyan's disclosed customer base (December 2022 IPO filing), a Chinese PEEK resin producer of this era would mainly sell to the following groups:
-
Stock-shape (profile) processors. These are converters of rod, sheet and tube. They made up about 66–71% of Zhongyan's revenue in 2019–2021.
-
Component moulders and machinists. These include makers of seals, bearings, compressor valve plates, wafer carriers and similar parts.
-
Traders and distributors, especially for export.
End-markets for PEEK at the time included electronics and semiconductors, industrial machinery, oil & gas and energy, automotive, aerospace and medical. Panjin Zhongrun's single verified grade was low-viscosity, unreinforced, rated UL 94 V-0, and also offered as powder. That profile suggests it targeted injection-moulding and coating or compression-moulding applications. Whether it achieved meaningful penetration in any end-market is not publicly disclosed.
Strategy
Stated strategy (historical, 2012)
No annual report or investor-day material exists. The only articulated strategy comes from the company's 2012 statements to the trade press, paraphrased here:
-
International expansion through distribution. The company signed with Bieglo to extend its reach in Europe, focusing on German-speaking markets and Belgium.
-
Competitive pricing paired with value-in-use. It positioned CoPEEK as cheaper than incumbent offerings, while arguing that customers ultimately choose on the added value of the material.
-
Platform breadth through patents. It held synthesis patents spanning the PAEK and polysulfone families, implying an intention to broaden into PSU, PES, PEES and PPSU.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
None identified. No partnerships, launches, ESG commitments, cost programmes or guidance from the company were found for this period. This is consistent with the revoked-licence status reported in December 2022.
Medium-term targets and guidance
Not publicly disclosed and not applicable.
Products & Services
Verified products
| Product | Description | Key specifications | Target customer | Launch / latest version | Pricing | Source |
|---|---|---|---|---|---|---|
| CoPEEK 085G | Semi-crystalline, low-viscosity, unreinforced polyetheretherketone | Unfilled; low melt viscosity; flame rating UL 94 V-0 (per supplier listing); also available as powder | Injection moulders; powder-coating and compression-moulding users (inferred from low viscosity and powder form) | c. 2011–2012 (inferred from European launch in 2012) | Not disclosed; marketed on price competitiveness | SpecialChem/Omnexus supplier page; Plasteurope (2012) |
| CoPEEK powder form | Powder version of the above | As above | Coating and moulding processors | — | — | SpecialChem/Omnexus |
| CoPEEK grade family (general) | Unspecified range of "CoPEEK grades" distributed in Europe by Bieglo | — | European processors, especially German-speaking markets and Belgium | 2,012 | — | Plasteurope (2012) |
| Polymer | Basis | Commercial evidence |
|---|---|---|
| Polysulfone (PSU) | Synthesis patent (1 of 4 patents covering multiple routes) | None found |
| Polyethersulfone (PES) | Synthesis patent | None found |
| Polyether ether sulfone (PEES) | Synthesis patent | None found |
| Biphenyl polyether ether sulfone (PPSU) | Synthesis patent | None found |
| Copolymerised PEEK (CoPEEK) | Synthesis patent | Commercialised (see 5.1) |
What "CoPEEK" means (analyst note)
The "Co-" prefix indicates a copolymerised PEEK. In this approach, part of the standard monomer set is replaced with a comonomer to change crystallinity, glass-transition temperature, or processability. The company has not publicly disclosed the exact comonomer chemistry. The 2012 interview stressed value-added performance as well as price, which suggests the copolymer was positioned as a differentiated grade and not a pure commodity substitute. This is analyst inference and has not been confirmed by the company.
Missing elements versus peers
Zhongyan disclosed 52 grades across six product series in its IPO prospectus: coarse powder (P), fine powder (PF), pellets (G), glass-fibre reinforced (GL), carbon-fibre reinforced (CA) and wear-resistant (FC). Compared with this, Panjin Zhongrun's verifiable catalogue is very narrow. No reinforced compounds, medical grades, film, fibre, or stock-shape products have been identified.
Financial Narrative
Disclosure position
No financial statements of Panjin Zhongrun High Performance Polymers have ever been publicly disclosed. The company is private, never filed with a securities regulator, and is reported to have a revoked business licence. Every financial metric below is therefore not publicly disclosed. No estimates are given, in line with the no-fabrication rule.
Some 2025–2026 market-research tables of contents (e.g., Gelonghui-hosted reports) include section headings promising this company's "sales, volume, price and gross margin 2021–2026." These are generic report templates. They should not be treated as company disclosures.
Ratios
ROE, ROA, ROIC, current ratio, debt/equity, net debt/EBITDA, interest coverage, asset turnover and the cash conversion cycle are all not publicly disclosed and not computable.
Peer financial reference: what a 1,000 t/y Chinese PEEK producer earns
The closest disclosed analogue gives context for the economics Panjin Zhongrun would have faced. Jilin Zhongyan ran the same Jilin-University-derived nucleophilic route at the same 1,000 t/y nameplate. Its figures are shown below. These are Zhongyan's figures, not Panjin Zhongrun's.
Source: Da Hua CPA / Zhongyan IPO inquiry response, SSE disclosure, 7 Dec 2022 (RMB 10k figures converted to RMB M).
Commentary. Even the domestic leader, which had established customers, used only 34–55% of its 1,000 t/y polymerisation capacity in 2019–2021. It generated roughly RMB 110–200 M of revenue. The filing put Chinese PEEK prices at RMB 300,000–600,000 per tonne. For Panjin Zhongrun to cover the fixed costs of a 1,000 t/y polymerisation plant, it would have needed comparable volumes. The 2017 directory, however, could not confirm any operating rate at all. The likely conclusion, which is analyst inference and has not been confirmed, is that the plant ran far below the scale needed to cover its fixed costs. That would be consistent with the later licence revocation.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Implied Operating Unit Details
| Implied operating unit | Contents | Status |
|---|---|---|
PAEK resins (CoPEEK) | Copolymerised PEEK powder and pellets (e.g., CoPEEK 085G) | Commercialised c. 2011–2012; current status inactive |
Polysulfone-family resins (PSU / PES / PEES / PPSU) | Patented synthesis methods | No evidence of commercial production |
Cash Flow and Operating Metrics (t)
| Metric (Zhongyan, peer benchmark) | FY2019 | FY2020 | FY2021 |
|---|---|---|---|
Operating revenue (CNY Mn) | 111.88 | 158.18 | 203.01 |
Coarse-powder capacity (t) | 1,000 | 1,000 | 1,000 |
Coarse-powder output (t) | 342.95 | 541.45 | 549.98 |
Coarse-powder capacity utilisation (%) | 34.29 | 54.14 | 55.00 |
Operating cash flow (CNY Mn) | 0.27 | 21.49 | 37.79 |
Capital Markets
| Metric | FY2021 |
|---|---|
Item | Status |
Analyst consensus | No coverage |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Domestic credit ratings | None identified |
Analyst Conclusions
Management guidance and consensus
None exists. There is no management guidance, no consensus, and no analyst coverage.
Bull case (revival or asset-value scenarios)
-
The asset could be monetised. China's PEEK demand has grown from 80 t (2012) to about 1,980 t (2021). New entrants plan more than 6,000 t/y of capacity. A permitted polymerisation site and patents in Panjin could therefore attract a buyer, as Victrex's 2020 choice of Panjin shows.
-
The IP portfolio has optional value. The four synthesis patents spanning PAEK and polysulfone resins could have licensing or sale value, provided they are still in force.
-
Market conditions are now favourable. Monomer supply is expanding to about 11,000 t/y of fluoroketone, and the leader runs at full utilisation. That suggests a capable operator could today sell volumes that were unreachable in 2012.
Bear case (base case)
-
The company is a non-operating shell. Licence revocation, recorded in December 2022, prevents lawful trading. No activity has been found for 2023–2026.
-
It has been left behind on scale. Zhongyan is building to 11,000 t/y, and Victrex has 1,500 t/y in the same city. A dormant 1,000 t/y CoPEEK line with a single verified grade has no viable route back to competitiveness.
-
Industry precedent points to exit. Kingfa, a far larger and better-capitalised company, also exited PEEK. Zhongyan itself cited both exits as evidence of high entry barriers.
Catalysts and monitorables (next 12 months)
| Monitorable | Why it matters |
|---|---|
| SAMR / National Enterprise Credit Information Publicity System status change (revoked → deregistered, or reinstated) | Confirms permanent exit or revival |
| Any court auction (司法拍卖) of Panjin assets or equipment | Possible asset transfer to a new entrant |
| Patent legal status on CNIPA | Determines residual IP value |
| Ramp-up of Panjin Victrex Xingfu | Shows the competitive intensity in the company's home cluster |
| Progress on Zhongyan's Zhangjiagang Phase 1 | Benchmark for domestic scale economics |
| SpecialChem/Omnexus listing removal | Signals that the remaining commercial footprint has been abandoned |
Concluding analyst verdict
Panjin Zhongrun High Performance Polymers is not an investable or currently operating company. It is best treated as a dormant, licence-revoked private entity. The input list's "public company" classification is wrong. The company never listed, never published financial statements, and has left almost no regulatory footprint. The single exception is a December 2022 STAR Market filing by its most successful rival, which cited it as an example of how hard PEEK synthesis is to commercialise.
The company's story is still instructive. Around 2009–2012 it got several strategic choices directionally right. It had a proven synthesis lineage from Jilin University, a differentiated copolymer brand, owned patents, a petrochemical-cluster location and an early European distributor. Its central error appears to have been timing and scale. It built about 1,000 t/y of nameplate capacity when all of China consumed under 100 t/y of PEEK. It then faced customer qualification cycles that can last up to two years, and incumbents that controlled the downstream stock-shape processors. Zhongyan ran the same chemistry at the same nameplate and used only 34–55% of its capacity as late as 2019–2021. It survived on a far broader product catalogue and a customer base anchored by large profile makers. Panjin Zhongrun, by contrast, has left evidence of only one commercial grade and no named customers.
Today the competitive gap is effectively unbridgeable. Zhongyan is building towards 11,000 t/y with integrated monomer supply, and Victrex has localised 1,500 t/y in Panjin itself. Any residual value is likely to lie in the site, its permits, or patents of uncertain legal status, and only if a new operator acquires them. Counterparties should verify the entity's current registry status directly through SAMR or Qichacha before any engagement. For exposure to Chinese PEEK through a listed vehicle, Jilin Zhongyan (688716.SH) is the appropriate subject of analysis.
Rating: Not rated / Not investable (inactive private entity).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Source |
|---|---|---|---|
Steven Xu (徐, given name not disclosed) | Marketing and Sales Director | At least 2012 | Plasteurope.com (3 May 2012) |
Major Shareholders
| Holder | Stake | Source |
|---|---|---|
Shenyang Zhongrun Chemical (reported parent) | Not disclosed (described as the group the company belonged to) | Plasteurope (2012) |
Institutional holders | Not applicable (unlisted) | — |
Competitive Landscape
Key Competitors
| # | Competitor | Country | Brand | Capacity (t/y) | Route | Relative position vs. Panjin Zhongrun | Source |
|---|---|---|---|---|---|---|---|
| 1 | Victrex plc | UK (LSE) | VICTREX | 7,150 (2018–2021) | ICI nucleophilic | Global leader, >60% global share (per Zhongyan filing); dominant | Zhongyan IPO response (2022) |
| 2 | Syensqo (formerly Solvay Specialty Polymers) | Belgium | KetaSpire | ~2,000 (2017 directory) | Gharda electrophilic | Tier-1 global | cmpe360 (2017) |
| 3 | Evonik Industries | Germany | VESTAKEEP | ~500 in Changchun (2017 directory; since expanded) | Jilin University nucleophilic | Tier-1 global with a China plant | cmpe360 (2017); Process Worldwide |
| 4 | Jilin Zhongyan Polymer Materials (688716.SH) | China | ZYPEEK | 1,000 (expanding by 10,000) | Jilin University nucleophilic | Domestic leader; about 8% global share per Northeast Securities (Feb 2024) | NESC (2024); CLS (2026) |
| 5 | Panjin Victrex Xingfu High Performance Materials (盘锦伟英兴) | China (Victrex 75%) | VICTREX | 1,500 planned | ICI nucleophilic | Same city; foreign-majority local capacity | Zhongyan IPO response (2022) |
| 6 | Changchun Jida Tesu Engineering Research (吉大特塑) | China | — | 100 PEEK (plus PEEKK, PEK, PES, PPSU at 100 each) | Jilin University nucleophilic | Small, broad portfolio | cmpe360 (2017) |
| 7 | Zhejiang Pengfulong (浙江鹏孚隆) | China | PFLUON | Expanding (not disclosed here) | — | Domestic tier-2 | Zhongyan IPO response (2022); NESC (2024) |
| 8 | Shandong Haoran Tesu (山东浩然特塑) | China | — | — | — | Domestic tier-2 | Zhongyan IPO response (2022) |
| 9 | Shandong Junhao High Performance Polymer (山东君昊), owned by Jiangsu Junhua | China | — |
| — | Vertically integrated stock-shape maker moving upstream | Zhongyan IPO response (2022); Everbright (2023) |
| 10 | Kingfa Sci & Tech | China | VisPEEK | ~300 (2017) | Jilin University nucleophilic | Exited PEEK per Zhongyan filing | cmpe360 (2017); Zhongyan IPO response (2022) |
| 11 | Jilin Juke, WOTE (沃特股份) and others | China | — |
| — | New entrants | Everbright Securities (Dec 2023) |
“—” = not publicly disclosed.
Peer Comparison FY2021
| Metric | Panjin Zhongrun | Victrex | Zhongyan | Syensqo (KetaSpire) |
|---|---|---|---|---|
PEEK nameplate capacity (t/y) | ≤1,000 (historical) | 7,150 | 1,000 (+10,000 planned) | ~2,000 (2017) |
Revenue | — | Group revenue < RMB 3 bn in 2021 (per Zhongyan filing) | RMB 203 M (FY2021) | Not split out |
Revenue growth | — | +25.23% PEEK volume (2021, per Zhongyan filing) | 34.70% CAGR (2019–2021) | Not split out |
Gross margin | — | Not compiled here | 44–53% by product (FY2021) | Not split out |
R&D intensity | — | Not compiled here | Not compiled here | Not split out |
Operating status | Licence revoked | Operating | Operating, full utilisation | Operating |
“—” = not publicly disclosed.
Recent Developments
Twenty-five entries cannot be produced without fabrication. Each is labelled [Industry].



